These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
106 related articles for article (PubMed ID: 12461034)
21. Selection of Bacillus anthracis isolates resistant to antibiotics. Athamna A; Athamna M; Abu-Rashed N; Medlej B; Bast DJ; Rubinstein E J Antimicrob Chemother; 2004 Aug; 54(2):424-8. PubMed ID: 15205405 [TBL] [Abstract][Full Text] [Related]
22. In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to four fluoroquinolones (levofloxacin, d-ofloxacin, ofloxacin, and ciprofloxacin), cefpirome, and meropenem. Hoppe JE; Rahimi-Galougahi E; Seibert G Antimicrob Agents Chemother; 1996 Mar; 40(3):807-8. PubMed ID: 8851619 [TBL] [Abstract][Full Text] [Related]
23. Bactericidal activity of levofloxacin and ciprofloxacin on clinical isolates of different phenotypes of Pseudomonas aeruginosa. Segatore B; Setacci D; Perilli M; Franceschini N; Marchetti F; Amicosante G Int J Antimicrob Agents; 2000 Jan; 13(3):223-6. PubMed ID: 10724029 [TBL] [Abstract][Full Text] [Related]
24. Comparative antimicrobial activities of gatifloxacin, sitafloxacin and levofloxacin against Mycobacterium tuberculosis replicating within Mono Mac 6 human macrophage and A-549 type II alveolar cell lines. Sato K; Tomioka H; Sano C; Shimizu T; Sano K; Ogasawara K; Cai S; Kamei T J Antimicrob Chemother; 2003 Aug; 52(2):199-203. PubMed ID: 12865388 [TBL] [Abstract][Full Text] [Related]
25. In vitro activities of levofloxacin, gatifloxacin, moxifloxacin and garenoxacin against Bacteroides fragilis strains evaluated by kill kinetics. Schaumann R; Janssen E; Funke M; Stîngu CS; Genzel GH; Janssen M; Rodloff AC J Med Microbiol; 2013 Apr; 62(Pt 4):576-581. PubMed ID: 23319309 [TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetic/pharmacodynamic modelling of the bactericidal activity of free lung concentrations of levofloxacin and gatifloxacin against Streptococcus pneumoniae. Tasso L; de Andrade C; Dalla Costa T Int J Antimicrob Agents; 2011 Oct; 38(4):307-13. PubMed ID: 21802907 [TBL] [Abstract][Full Text] [Related]
30. Susceptibility to antibiotics of Bacillus anthracis strains isolated in Romania. Caplan DM; Ivana S; Caplan ME Roum Arch Microbiol Immunol; 2009; 68(2):106-10. PubMed ID: 20361530 [TBL] [Abstract][Full Text] [Related]
31. Concentration-dependent killing of antibiotic-resistant pneumococci by the methoxyquinolone moxifloxacin. Klugman KP; Capper T J Antimicrob Chemother; 1997 Dec; 40(6):797-802. PubMed ID: 9462430 [TBL] [Abstract][Full Text] [Related]
32. Evaluation of Combination Drug Therapy for Treatment of Antibiotic-Resistant Inhalation Anthrax in a Murine Model. Heine HS; Shadomy SV; Boyer AE; Chuvala L; Riggins R; Kesterson A; Myrick J; Craig J; Candela MG; Barr JR; Hendricks K; Bower WA; Walke H; Drusano GL Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28696235 [No Abstract] [Full Text] [Related]
33. Antibacterial effects of moxifloxacin and levofloxacin simulating epithelial lining fluid concentrations against community-acquired methicillin-resistant Staphylococcus aureus. Lee SY; Fan HW; Sutherland C; DeRyke AC; Nicolau DP Drugs R D; 2007; 8(2):69-77. PubMed ID: 17324004 [TBL] [Abstract][Full Text] [Related]
34. Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin. LaPlante KL; Rybak MJ; Tsuji B; Lodise TP; Kaatz GW Antimicrob Agents Chemother; 2007 Apr; 51(4):1315-20. PubMed ID: 17296740 [TBL] [Abstract][Full Text] [Related]
35. In-vitro bacteriostatic activity of levofloxacin and three other fluoroquinolones against penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae. Frémaux A; Sissia G; Geslin P J Antimicrob Chemother; 1999 Jun; 43 Suppl C():9-14. PubMed ID: 10404331 [TBL] [Abstract][Full Text] [Related]
36. Comparative in vitro activity of meropenem versus other extended-spectrum antimicrobials against randomly chosen and selected resistant clinical isolates tested in 26 North American centers. Pitkin DH; Sheikh W; Nadler HL Clin Infect Dis; 1997 Feb; 24 Suppl 2():S238-48. PubMed ID: 9126699 [TBL] [Abstract][Full Text] [Related]
37. In vitro post-antibiotic effect of fluoroquinolones, macrolides, beta-lactams, tetracyclines, vancomycin, clindamycin, linezolid, chloramphenicol, quinupristin/dalfopristin and rifampicin on Bacillus anthracis. Athamna A; Athamna M; Medlej B; Bast DJ; Rubinstein E J Antimicrob Chemother; 2004 Apr; 53(4):609-15. PubMed ID: 14998982 [TBL] [Abstract][Full Text] [Related]
38. Urinary concentrations and bactericidal activities of newer fluoroquinolones in healthy volunteers. Stein GE; Schooley S Int J Antimicrob Agents; 2004 Aug; 24(2):168-72. PubMed ID: 15288316 [TBL] [Abstract][Full Text] [Related]
39. [In vitro activity of six fluoroquinolones and penicillin against 101 viridans group streptococci characterized by their susceptibility to erythromycin]. Rodríguez-Avial I; Rodríguez-Avial C; Picazo JJ Rev Esp Quimioter; 2001 Dec; 14(4):364-8. PubMed ID: 11856983 [TBL] [Abstract][Full Text] [Related]
40. In vitro activity of tetracyclines, macrolides, quinolones, clindamycin and metronidazole against periodontopathic bacteria. Miyake Y; Tsuruda K; Okuda K; Widowati ; Iwamoto Y; Suginaka H J Periodontal Res; 1995 Jul; 30(4):290-3. PubMed ID: 7562327 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]